Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

New England Journal of Medicine

Volumn 378, Issue 5, 2018, Pages 439-448

  Maude, S L ^a,d   Laetsch, T W ^e   Buechner, J ^f   Rives, S ^g   Boyer, M ^h   Bittencourt, H ⁱ   Bader, P ^k   Verneris, M R ^l   Stefanski, H E ^l   Myers, G D ^m   Qayed, M ⁿ   De Moerloose, B ^o   Hiramatsu, H ^p   Schlis, K ^q   Davis, K L ^q   Martin, P L ^s   Nemecek, E R ^t   Yanik, G A ^u   Peters, C ^v   Baruchel, A ^w   Boissel, N ^x   Mechinaud, F ^y   Balduzzi, A ^z   Krueger, J ^j   June, C H ^b,c   Levine, B L ^b,c   Wood, P ^aa   Taran, T ^aa   Leung, M ^aa   Mueller, K T ^ab   Zhang, Y ^aa   Sen, K ^aa   Lebwohl, D ^aa   Pulsipher, M A ^r   Grupp, S A ^a,d   more..

^a 3012 Colket Translational Research Bldg   (United States)

^b Department of Pathology and Laboratory Medicine ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g HOSPITAL SANT JOAN DE DÉU   (Spain)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l UNIVERSITY OF MINNESOTA   (United States)

^m CHILDREN S MERCY HOSPITAL   (United States)

ⁿ EMORY UNIVERSITY   (United States)

^o GHENT UNIVERSITY HOSPITAL   (Belgium)

^p KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

^t OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^u UNIVERSITY OF MICHIGAN   (United States)

^v ST ANNA CHILDREN S HOSPITAL   (Austria)

^w HÔPITAL ROBERT DEBRÉ   (France)

^x SAINT LOUIS HOSPITAL   (France)

^y ROYAL CHILDREN'S HOSPITAL   (Australia)

^z UNIVERSITY OF MILANO BICOCCA   (Italy)

^aa NOVARTIS PHARMA AG   (Switzerland)

^ab NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILEUKEMIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD19 ANTIGEN; HYPERTENSIVE FACTOR; OXYGEN; TISAGENLECLEUCEL T; TOCILIZUMAB; ANTINEOPLASTIC AGENT; CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGITATION; ARTICLE; B CELL LEUKEMIA; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; BRAIN EDEMA; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONFUSION; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DECREASED APPETITE; DELIRIUM; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HUMAN; HUMAN CELL; HYPERVOLEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LUNG EDEMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PLATELET COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; TUMOR LYSIS SYNDROME; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORTALITY; REMISSION; SURVIVAL ANALYSIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD19; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85041428116     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1709866     Document Type: Article

References (21)

1. Maude SL, Teachey DT, Rheingold SR, et al. Sustained remissions with CD19- specific chimeric antigen receptor (CAR)- modified T cells in children with relapsed/refractory ALL. J Clin Oncol 2016; 34: Suppl 15: 3011. abstract.
2. Grupp SA, Maude SL, Shaw PA, et al. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood 2015; 126: 681. abstract.
3. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-64.
4. Grupp SA, Laetsch TW, Buechner J, et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood 2016; 128: 221. abstract.
5. Janetzki S, Britten CM, Kalos M, et al. "MIATA"-minimal information about T cell assays. Immunity 2009; 31: 527-8.
6. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-18.
7. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 1917-23.
8. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 2016; 34: 4381-9.
9. Shah B, Huynh V, Sender LS, et al. High rates of minimal residual diseasenegative (MRD-) complete responses (CR) in adult and pediatric and patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cells): preliminary results of the ZUMA-3 and ZUMA-4 trials. Blood 2016; 128: 2803. abstract.
10. Lee DW, Stetler-Stevenson M, Yuan CM, et al. Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation. Blood 2016; 128: 218. abstract.
11. Gardner R, Finney O, Smothers H, et al. CD19CAR T cell products of defined CD4:CD8 composition and transgene expression show prolonged persistence and durable MRD-negative remission in pediatric and young adult B-cell ALL. Blood 2016; 128: 219. abstract.
12. Sabatino M, Choi K, Chiruvolu V, Better M. Production of anti-CD19 CAR T cells for ZUMA-3 and -4: phase 1/2 multicenter studies evaluating KTE-C19 in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL). Blood 2016; 128: 1227. abstract.
13. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-28.
14. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy- refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra38.
15. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21: 581-90.
16. Lee DW, Stetler-Stevenson M, Yuan CM, et al. Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia. Blood 2015; 126: 684. abstract.
17. Abramson JS, Palomba ML, Gordon LI, et al. CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19- directed CAR T-cell product JCAR017 (TRANSCEND NHL 001). J Clin Oncol 2017; 35: Suppl 15: 7513. abstract.
18. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 2017; 129: 3322-31.
19. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126: 2123-38.
20. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7: 303ra139.
21. Gardner R, Leger KJ, Annesley CE, et al. Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management. Blood 2016; 128: 586. abstract.